Close Menu

NEW YORK – A group of researchers led by the University of East Anglia in the UK have developed a urine-derived extracellular vesicle RNA (UEV-RNA) tool – called Prostate Urine Risk (PUR) – that provides diagnostic data about disease status and prognostic information for patients on active surveillance (AS) before tissue biopsy.

The researchers believe that the PUR tool can identify patients who may need treatment up to five years in advance, thereby potentially minimizing the need for repeated checkups for low-risk patients on AS. 

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

This webinar will provide an overview of how an international reference laboratory has implemented an automated next-generation sequencing workflow with custom panels for analyzing cancer samples.


This webinar will provide an overview of how a pathology laboratory validated a 77-gene next-generation sequencing-based liquid biopsy assay.


This webinar will tell the story of Versiti’s journey in transforming genetic testing from a manual to a digitized process. It will include detail on how the organization succeeded, pain points along the way, a novel approach to variant assessment, and future plans for the program.